Treatment with anti-vegf antibodies

Abstract

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

1 . A kit for treating metastatic colorectal cancer in a human patient comprising a package comprising an anti-VEGF antibody composition and instructions for using the anti-VEGF antibody composition in combination with IFL (irinotecan, 5-fluorouracil and leucovorin), wherein the instructions further comprise  FIG. 1 . 
     
     
         2 . A kit for treating metastatic colorectal cancer in a human patient comprising a package comprising an anti-VEGF antibody composition and instructions for using the anti-VEGF antibody composition in combination with IFL, wherein the instructions recite that the medium survival for patients receiving IFL and bevacizumab is 20.3 months with a hazard ratio of 0.66. 
     
     
         3 . A kit for treating metastatic colorectal cancer in a human patient comprising a package comprising an anti-VEGF antibody composition and instructions for using the anti-VEGF antibody composition in combination with IFL, wherein the instructions recite that the progression free survival for patients receiving IFL and bevacizumab is 10.6 months with a hazard ratio of 0.54. 
     
     
         4 . A kit for treating metastatic colorectal cancer in a human patient comprising a package comprising an anti-VEGF antibody composition and instructions for using the anti-VEGF antibody composition in combination with IFL, wherein the instructions recite that the median duration of response for patients receiving IFL and bevacizumab is 10.4 months. 
     
     
         5 . A kit for treating a cancer patient comprising a package comprising an anti-VEGF antibody composition and instructions for using the anti-VEGF antibody in combination with at least one chemotherapeutic agent, wherein the instructions provide information about the risk of gastrointestinal perforation during treatment with the anti-VEGF antibody composition. 
     
     
         6 . The kit of any one of  claims 1 - 5 , wherein the anti-VEGF antibody has a heavy chain variable region comprising the following amino acid sequence: 
       
         
           
                 
                 
               
                   (SEQ ID No. 1) 
                     
                 
                 
                 
               
                   EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWVRQA 
                     
                 
                     
                 
                   PGKGLEWVGW INTYTGEPTY AADFKRRFTF SLDTSKSTAY 
                 
                     
                 
                   LQMNSLRAED TAVYYCAKYP HYYGSSHWYF DVWGQGTLVT VSS 
                 
             
                
               
            
             
                
                
                
                
                
               
            
           
         
       
       and a light chain variable region comprising the following amino acid sequence: 
       
         
           
                 
                 
               
                   (SEQ ID No. 2) 
                     
                 
                 
                 
                 
               
                     
                   DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP 
                     
                 
                     
                     
                 
                     
                   GKAPKVLIYF TSSLHSGVPS RFSGSGSGTD FTLTISSLQP 
                 
                     
                     
                 
                     
                   EDFATYYCQQ YSTVPWTFGQ GTKVEIKR. 
                 
             
                
               
            
             
                
                
                
                
                
               
            
           
         
       
     
     
         7 . The kit of  claim 6 , wherein the anti-VEGF antibody is bevacizumab. 
     
     
         8 . The kit of any one of  claims 1 - 5 , wherein the patient is previously untreated.